Adjuvant chemotherapy (AC) with S-1 after radical surgery for resectable pancreatic cancer (PC) has shown a significant survival advantage over surgery alone. Consequently, ensuring that patients receive a consistent, uninterrupted S-1 regimen is of paramount importance. This study aimed to investigate whether the C-reactive protein-to-albumin ratio (CAR) could predict S-1 AC completion in PC patients without dropout due to adverse events (AEs). We retrospectively enrolled 95 patients who underwent radical pancreatectomy and S-1 AC for PC between January 2010 and December 2022. A statistical analysis was conducted to explore the correlation of predictive markers with S-1 completion, defined as continuous oral administration for 6 months. Among the 95 enrolled patients, 66 (69.5%) completed S-1, and 29 (30.5%) failed. Receiver operating characteristic curve analysis revealed 0.05 as the optimal CAR threshold to predict S-1 completion. Univariate and multivariate analyses further validated that a CAR ≥ 0.05 was independently correlated with S-1 completion (p< 0.001 andp= 0.006, respectively). Furthermore, a significant association was established between a higher CAR at initiation of oral administration and acceptable recurrence-free and overall survival (p= 0.003 andp< 0.001, respectively). CAR ≥ 0.05 serves as a predictive marker for difficulty in completing S-1 treatment as AC for PC due to AEs.
对于可切除胰腺癌（PC）根治术后患者，S-1辅助化疗（AC）相较于单纯手术已显示出显著的生存获益。因此，确保患者接受持续、不间断的S-1治疗方案至关重要。本研究旨在探讨C反应蛋白与白蛋白比值（CAR）能否预测胰腺癌患者在不因不良事件（AEs）中断治疗的情况下完成S-1辅助化疗。我们回顾性纳入了2010年1月至2022年12月期间接受胰腺癌根治性切除术及S-1辅助化疗的95例患者。通过统计分析探究预测标志物与S-1治疗完成情况（定义为持续口服给药6个月）的相关性。在入组的95例患者中，66例（69.5%）完成S-1治疗，29例（30.5%）未能完成。受试者工作特征曲线分析显示，0.05是预测S-1治疗完成的最佳CAR临界值。单因素和多因素分析进一步证实，CAR≥0.05与S-1治疗完成情况独立相关（分别为p<0.001和p=0.006）。此外，研究还发现口服给药起始时较高的CAR值与可接受的无复发生存期和总生存期显著相关（分别为p=0.003和p<0.001）。CAR≥0.05可作为预测胰腺癌患者因不良事件难以完成S-1辅助化疗的生物学标志物。
肿瘤(癌症)患者之家